Edwards Lifesciences
About: Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.
Employees: 15,800
0
Funds holding %
of 7,296 funds
0
Analysts bullish %
of 5 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
45% more call options, than puts
Call options by funds: $257M | Put options by funds: $178M
0.21% less ownership
Funds ownership: 85.07% [Q4 2024] → 84.86% (-0.21%) [Q1 2025]
3% less first-time investments, than exits
New positions opened: 118 | Existing positions closed: 122
4% less capital invested
Capital invested by funds: $37.5B [Q4 2024] → $36B (-$1.48B) [Q1 2025]
3% less funds holding
Funds holding: 1,205 [Q4 2024] → 1,172 (-33) [Q1 2025]
10% less funds holding in top 10
Funds holding in top 10: 10 [Q4 2024] → 9 (-1) [Q1 2025]
21% less repeat investments, than reductions
Existing positions increased: 377 | Existing positions reduced: 478
Research analyst outlook
5 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$75
0%
upside
Avg. target
$81
7%
upside
High target
$95
26%
upside
5 analyst ratings
2 positive
40%
3 neutral
60%
0 negative
0%
Citigroup Joanne Wuensch | 26%upside $95 | Buy Maintained | 22 May 2025 |
Piper Sandler Adam Maeder | 10%upside $83 | Overweight Maintained | 13 May 2025 |
Canaccord Genuity William Plovanic | 0%downside $75 | Hold Maintained | 25 Apr 2025 |
Baird David Rescott | 0%downside $75 | Neutral Maintained | 24 Apr 2025 |
Truist Securities Richard Newitter | 0%downside $75 | Hold Maintained | 11 Apr 2025 |
Financial journalist opinion
Based on 6 articles about EW published over the past 30 days
Positive
Seeking Alpha
1 week ago
Edwards Lifesciences: With A Heart Beating Strong And Steady
Edwards Lifesciences is a high-quality, dominant player in structural heart medical devices, with a solid growth history and strong cash generation. The TMTT segment is now the main growth engine, showing rapid expansion, while TAVR growth has plateaued but remains stable. Strategic acquisitions and robust R&D investment position EW for continued innovation and long-term revenue growth above S&P 500 averages.
Neutral
Investors Business Daily
2 weeks ago
How Boston Scientific's Surprise Setback Bolstered Edwards, Medtronic, Abbott
Edwards Lifesciences stock jumped Wednesday after Boston Scientific said it would stop selling its rival heart-valve replacement systems.
Positive
Zacks Investment Research
3 weeks ago
Edwards' New Late-Breaking Data on Severe AS Expected to Boost Stock
EW's new late-breaking clinical data shows early intervention in AS may slash significant costs and improve patient outcomes.
Neutral
Business Wire
3 weeks ago
Prompt Intervention for Severe Aortic Stenosis Patients Demonstrates Lower Healthcare Costs, Improved Clinical Outcomes
PARIS--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced new economic and clinical evidence on severe aortic stenosis (AS) presented as a late-breaking clinical trial at EuroPCR 2025, further contributing to the extensive body of research on this disease. The results of a new real-world study of more than 24,000 patients demonstrated that intervening on the disease before symptoms develop reduces the economic and resource burden on the healthcare system and improves patient outco.
Positive
CNBC Television
3 weeks ago
Trade Tracker: Bill Baruch buys Edwards Lifesciences
Bill Baruch, founder & president at Blue Line Capital, joins CNBC's 'Halftime Report' to detail his latest buy.
Positive
Zacks Investment Research
1 month ago
Should Edwards Lifesciences Stock Remain in Your Portfolio Now?
EW stock is on investors' radars due to the promising structural heart opportunities and impressive TMTT portfolio.
Neutral
Business Wire
1 month ago
Edwards Lifesciences to Present at the BofA Securities 2025 Health Care Conference
IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced it will participate in the BofA Securities 2025 Health Care Conference on Tuesday, May 13, 2025. Bernard Zovighian, chief executive officer, and Scott Ullem, chief financial officer, will participate in a fireside chat at 10:40 a.m. Pacific Time. A live webcast of the discussion will be available on the Edwards Lifesciences investor relations website at http://ir.edwards.com, with an archived version accessible lat.
Neutral
Business Wire
1 month ago
Edwards TAVR Receives FDA Approval for Patients With Asymptomatic Severe Aortic Stenosis
IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) announced today that the U.S. Food and Drug Administration (FDA) has approved its transcatheter aortic valve replacement (TAVR) therapy, the SAPIEN 3 platform, for severe aortic stenosis (AS) patients without symptoms, marking the first FDA approval for TAVR in asymptomatic patients. Approval of the SAPIEN 3 platform (SAPIEN 3, SAPIEN 3 Ultra and SAPIEN 3 Ultra RESILIA) is based on groundbreaking data from the EARLY TAVR trial, wh.
Positive
Benzinga
1 month ago
Edwards Lifesciences Stock Earns Analyst Upgrade As Growth Outlook Brightens
Edwards Lifesciences‘ EW shares are trading higher Thursday after the company reported first-quarter 2025 sales of $1.41 billion.
Positive
Zacks Investment Research
1 month ago
EW Q1 Earnings & Revenues Beat, Stock Climbs, '25 Sales View Raised
Edwards Lifesciences' first-quarter 2025 performance benefits from its differentiated portfolio of therapies to treat patients with structural heart disease.
Charts implemented using Lightweight Charts™